Harvest Technologies Corporation Granted CE Mark for Expanded Clinical Indication for Treatment of No-Option Critical Limb Ischemia

Informations

• Publié par: HARVEST-TECHNOLOGIES-CORPORATION
• Nombre de lectures: 9
• Langue: English

Extrait

Harvest Technologies Corporation Granted CE Mark for Expanded Clinical Indication for Treatment of No-Option Critical Limb Ischemia

PR Newswire PLYMOUTH, Massachusetts, Nov. 19, 2012

PLYMOUTH, Massachusetts,Nov. 19, 2012/PRNewswire/ -- Harvest Technologies, a leader in advancing cellular therapies, is pleased to announce CE Marking for an expanded clinical indication for its SmartPReP®2 Bone Marrow Aspiration Concentration System (BMAC®2) product.

The British Standards Institution (BSI), a notified body under the Medical Device Directive, has awarded a certificate indicating that the Harvest SmartPReP2 Bone Marrow Aspiration Concentrate System (BMAC2) is intended to be used at point-of-care for the safe and rapid preparation of autologous nucleated cell concentrate from Bone Marrow Aspiration (BMA) foradministration into ischemic tissues of the affected limb due to No-Option Critical Limb Ischemia.

This is the first time an autologous point-of-care cellular therapy company has presented sufficient clinical evidence for a notified body to grant approval to promote a specific product for this clinical use.

This certification comes after BSI's extensive review of clinical data from nearly 50 clinical trials and investigations, including data using Harvest Technologies BMAC2 System. Previous studies have shown that critical lim b ischemia (CLI) patients that have tissue loss (gangrenous or ulcer wounds) are at severe risk for amputation. Harvest studies have shown that the use of the BMAC 2 system significantly reduces that risk and is a viable option for limb salvage. The Harvest studies have also been able to show improvement in rest pain for patients with severe rest pain.

"We are pleased about the expansion of our claims. This indication provides a significant treatment option that can improve the quality of life for approximately 800,000 European patients annually that progress to end stage critical limb ischemia," said Gary Tureski, President and CEO, Harvest Technologies Corporation. "The clinical evidence from our European studies is so compelling that we committed to and are currently enrolling patients in a US FDA pivotal trial."

Harvest Technologies is the leading Cellular Therapy global manufacturer that develops point-of-care products to process and concentrate multiple biologics. These include high-density platelet rich plasma (APC+®), bone marrow aspirate concentrate (BMAC®) and adipose tissue. The company is headquartered in Plymouth, Massachusetts. It is one of several subsidiaries of Terumo Corporation of Japan that is focused in cellular therapies and biologics. For more information, visitwww.harvesttech.com.

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with$5 billionin sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use.

Harvest Technologies Corporation Plymouth, MA 02360 [phone]

Harvest, SmartPReP and BMAC are registered trademarks of Harvest Technologies Corporation. Terumo® is a registered trademark of Terumo Corporation.